Céline Druart is the Pharmabiotic Research Institute’s (PRI) Executive Director since January 2024. She joined the PRI in July 2021 as Microbiome Project Manager, managing the Regulatory Science activities of the Association, coordinating Task Group work, and supporting PRI Industry Members in their development planning.  

The PRI is Europe’s leading center in microbiome regulatory science. “Microbiome regulatory science” refers to the study and development of regulatory frameworks, standards, and guidelines for products, therapies, and interventions that involve or affect the microbiome. Established in 2010 as a non-profit organization, the PRI supports the development of microbiome-based innovations by clarifying the regulatory and scientific requirements needed to access the European market.

Céline Druart obtained her PhD in Biomedical and Pharmaceutical Sciences from UCLouvain (Belgium) in 2014. Following a 3-year project in Patrice Cani’s research group focused on developing the potential beneficial effects of a human gut commensal Akkermansia muciniphila, she worked for 3 years at A-Mansia Biotech (now known as The Akkermansia Company), responsible for clinical programs, regulatory affairs and IP dossiers, as the Scientific and Business Project Manager.